Milton Werner

Milton Werner

Company: Inhibikase Therapeutics

Job title: Founder, President & CEO


Providing the First Mechanistic Basis for Halting Neurodegenerative Disease: Targeting c-Abl to Reverse Parkinson’s Disease 9:30 am

Discussing the discovery of the biochemical process underlying the initiation and progression of Parkinson’s disease to rationalize c-Abl targeting Optimizing drug design of c-Abl inhibitor IkT-148009 to halt Parkinson’s disease and restore functional loss to effectively reverse Parkinson’s disease Reflecting on preclinical data to supercharge phase 1 trials for IkT-148009Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.